Business
TVG's vaccine candidate enters animal trials
TVG's vaccine candidate enters animal trials.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n\nREACH - a non-regulatory announcement\nAIM: FIPP\n06 May 2025\n \nFrontier IP Group plc\n(\"Frontier IP\" or the \"Group\")\n \n \nPortfolio news - The Vaccine Group's African Swine Fever vaccine candidate enters animal trials\n \nFrontier IP, a specialist in commercialising intellectual property, today notes the following announcement from portfolio company The Vaccine Group (\"TVG\" or the \"Company\") that a vaccine candidate developed in collaboration with The Pirbright Institute to combat African Swine Fever (\"ASF\") has entered animal trials.\n \nASF is a highly contagious, epidemic and viral disease that can prove fatal to pigs. In some cases, mortality rates reach 100 per cent. The economic effects are severe. Steps to fight the disease include mass culling, export restrictions and other trade disruptions. In China alone, ASF is estimated to have caused economic damage worth $119 billion in a decade1 , with a particularly bad outbreak in 2019 resulting in a 0.8 per cent hit to Chinese GDP2. Since 2022, it has been reported in 64 countries.\n \nThere are no safe and effective vaccines currently available. University of Plymouth spin out TVG and The Pirbright Institute started collaborating on a vaccine in 2024, a project backed by funding through a Biotechnology and Biological Sciences Research Council (\"BBSRC\") Industrial Partnership Award. The BBSRC is part of UK Research and Innovation.\n \nThe ASF vaccine candidate is part of an expanding pipeline of vaccines and biotherapeutics being developed by TVG targeting 12 different livestock and companion animal diseases.\n \nFrontier IP holds a 16.7 per cent equity stake in the Company.\n \n \nFrontier IP Chief Executive Officer Neil Crabb said: \"The ASF vaccine entering animal trials is an important milestone, not just for TVG, but more broadly for efforts to stop this devastating disease. ASF has now emerged as a rapidly spreading global threat, yet there is no safe and effective vaccine - and vaccines are the most potent means of preventing disease.\"\n \n \n \n1Schulz, K., C. Staubach, S. Blome, I. Nurmoja, A. Viltrop and F.J. Conraths. 2019. African swine fever: Fast and furious or slow and steady? Viruses 11(10), 86\n \n2https://www.nature.com/articles/s43016-021-00362-\n \n \...